Exact Mass: 498.255

Exact Mass Matches: 498.255

Found 500 metabolites which its exact mass value is equals to given mass value 498.255, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Moexipril

[3S-[2[R*(R*)],3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, monohydrochloride;[3S-[2[R*(R*)],3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid, monohydrochloride

C27H34N2O7 (498.2366)

Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems. C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09A - Ace inhibitors, plain > C09AA - Ace inhibitors, plain D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents

2-[2-[(1-Ethoxy-1-oxo-4-phenylbutan-2-yl)amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid

2-{2-[(1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino]propanoyl}-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid

C27H34N2O7 (498.2366)

D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents

beta-Alanine, N-(N-(2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-2-oxo-1-(phenylmethyl)ethyl)-L-phenylalanyl)-

3-{[2-({1-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-1-oxo-3-phenylpropan-2-yl}amino)-1-hydroxy-3-phenylpropylidene]amino}propanoate

C27H34N2O7 (498.2366)

Sograzepide

N-[1-(3,3-Dimethyl-2-oxobutyl)-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-n-[3-(methylamino)phenyl]carbamimidate

C28H30N6O3 (498.2379)

Avapritinib

(1S)-1-(4-fluorophenyl)-1-(2-{4-[6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]piperazin-1-yl}pyrimidin-5-yl)ethan-1-amine

(1R,2S,4aR,6aS,6bR,8R,12aS,12bS,12cS,13aS,13bS,13cR)-1,3,4,5,6,6a,6b,7,8,12a,12b,12c,13a,13c-tetradecahydro-2,8,11-trihydroxy-1,2,6a,6b,9,12a-hexamethyl-2H,10H-13b,4a-(epoxymethano)piceno[13,14-b]oxirene-10,15-dione|2,6beta,20beta-trihydroxy-3-oxo-11alpha,12alpha-epoxy-24-norursa-1,4-dien-28,13beta-olide|asprellol A

NCGC00347645-02_C28H38N2O6_1,9-Dioxacyclohexadeca-3,11-diene-2,10-dione, 3,5,7,11,13,15-hexamethyl-8,16-bis(5-oxazolylmethyl)-, (3E,5S,7R,8R,11E,13S,15R,16R)-

C28H38N2O6 (498.273)

Octanoic acid, 1-[[[(2,3-dihydroxypropoxy)hydroxyphosphinyl]oxy]methyl]-1,2-ethanediyl ester, (R)-

C22H43O10P (498.2594)

Petromylidene C

2-(E)-ethylidene-7alpha,12alpha,24-trihydroxy-5alpha-cholan-3-one-24-sulfate

C26H42O7S (498.2651)

1-ETHYLOXYCARBONYL-3-[4-(4-METHYL-PIPERAZIN-1-YL)-BENZOYLAMINO]-5-BOC-4,6-DIHYDRO-PYRROLO[3,4-C]PYRAZOLE

C25H34N6O5 (498.2591)

Simetride

2-(2-methoxy-4-propylphenoxy)-1-[4-[2-(2-methoxy-4-propylphenoxy)acetyl]piperazin-1-yl]ethanone

C28H38N2O6 (498.273)

C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent

Teludipine

C28H38N2O6 (498.273)

acrihellin

C29H38O7 (498.2617)

Sograzepide

C28H30N6O3 (498.2379)

C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent C308 - Immunotherapeutic Agent > C63817 - Chemokine Receptor Antagonist Sograzepide?(Netazepide; YF 476; YM-220) is an extremely?potent?, highly?selective?and orally active Gastrin/CCK-B antagonist with an IC50 value of 0.1 nM, has inhibitory effect on Gastrin/CCK-A activity with an IC50 of 502 nM[1]. Sograzepide?(Netazepide; YF 476; YM-220) replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine and cloned human?Gastrin/CCK-B receptors, with Ki values of 0.068, 0.62 and 0.19 nM, respectively[2].

Avapritinib

C26H27FN10 (498.2404)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor

Gdc-0152

C25H34N6O3S (498.2413)

C274 - Antineoplastic Agent > C129839 - Apoptotic Pathway-targeting Antineoplastic Agent

CCK-B Receptor Antagonist 1

Moexipril

ST 29:7;O7

C29H38O7 (498.2617)

Mutant IDH1-IN-1

C30H31FN4O2 (498.2431)

C29H38O7 (498.2617)

{"Ingredient_id": "HBIN005265","Ingredient_name": "2\u03b1-acetoxy-4\u03b2-hydroxy-6\u03b1-angeloyloxy-10\u03b2-benzoyloxy-dauc-8-ene","Alias": "NA","Ingredient_formula": "C29H38O7","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "207","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

(1s,2s,4r,6s,11r,12s,14s,17r,18r,21s)-17-[(2r)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]-18-hydroxy-14-methoxy-11,21-dimethyl-5,15-dioxahexacyclo[12.6.1.0²,¹².0⁴,⁶.0⁶,¹¹.0¹⁸,²¹]henicos-8-en-10-one

(1s,4ar,6s,7r,7as)-4a,6-dihydroxy-1-[(3-methylbutanoyl)oxy]-1,5,6,7a-tetrahydrospiro[cyclopenta[c]pyran-7,2'-oxiran]-4-ylmethyl (2r)-3-methyl-2-[(3-methylbutanoyl)oxy]butanoate

C25H38O10 (498.2465)

[(1r,3ar,6s,7s,8r,9ar,9br,11ar)-7,8-dihydroxy-1-[(1s)-1-[(2s,3s)-3-isopropyloxiran-2-yl]ethyl]-9a,11a-dimethyl-1h,2h,3h,3ah,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-6-yl]oxidanesulfonic acid

[(1r,3ar,6s,7s,8r,9ar,9br,11ar)-7,8-dihydroxy-1-[(1s)-1-[(2s,3s)-3-isopropyloxiran-2-yl]ethyl]-9a,11a-dimethyl-1h,2h,3h,3ah,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-6-yl]oxidanesulfonic acid

(1s,2s,3r,4r,6r,8s,9r,10s,11s,14r,15r,17r)-3-(acetyloxy)-2,4,10,11,15-pentahydroxy-5,5,10,15-tetramethyl-7-oxapentacyclo[12.2.1.0¹,¹¹.0⁴,⁹.0⁶,⁸]heptadecan-17-yl propanoate

C25H38O10 (498.2465)

(1s,4as,6s,7r,7as)-4a,6-dihydroxy-1-[(3-methylbutanoyl)oxy]-1,5,6,7a-tetrahydrospiro[cyclopenta[c]pyran-7,2'-oxiran]-4-ylmethyl 3-methyl-2-[(3-methylbutanoyl)oxy]butanoate

C25H38O10 (498.2465)

(1s,2s,4r,6s,11r,12s,14s,16r,17r,18r,21s)-16-[(2r)-3,4-dimethyl-5-oxo-2h-furan-2-yl]-18-hydroxy-14-methoxy-11,17,21-trimethyl-5,15-dioxahexacyclo[12.6.1.0²,¹².0⁴,⁶.0⁶,¹¹.0¹⁸,²¹]henicos-8-en-10-one

(1s,2s,4r,6s,11r,12s,14s,16r,17r,18r,21s)-16-[(2r)-3,4-dimethyl-5-oxo-2h-furan-2-yl]-18-hydroxy-14-methoxy-11,17,21-trimethyl-5,15-dioxahexacyclo[12.6.1.0²,¹².0⁴,⁶.0⁶,¹¹.0¹⁸,²¹]henicos-8-en-10-one

C29H38O7 (498.2617)

(1s,3r,7r,8s,9s,11s)-9-hydroxy-9-{2-[(1r,6r,8r)-6-hydroxy-10,10-dimethyl-4-oxotricyclo[6.3.0.0²,⁶]undec-2-en-3-yl]ethyl}-5,5-dimethyl-10-oxo-12-oxatetracyclo[6.4.0.0¹,¹¹.0³,⁷]dodecane-8-carboxylic acid

(1s,3r,7r,8s,9s,11s)-9-hydroxy-9-{2-[(1r,6r,8r)-6-hydroxy-10,10-dimethyl-4-oxotricyclo[6.3.0.0²,⁶]undec-2-en-3-yl]ethyl}-5,5-dimethyl-10-oxo-12-oxatetracyclo[6.4.0.0¹,¹¹.0³,⁷]dodecane-8-carboxylic acid

C28H38N2O6 (498.273)